Choosing software for a genetic testing lab is really a question about your whole operation: how an order becomes a sample, a sample becomes a report, and a report becomes a paid claim. This guide covers the capabilities that matter, how to evaluate vendors, and the trade-off between one platform and a stitched-together stack.
The short version
- A genetic testing lab needs six things from its software: LIS/LIMS operations, reporting, integrations, portals, billing, and security — plus responsible AI.
- The biggest decision is one integrated platform vs several stitched-together tools. Silos are where delays and errors come from.
- Watch for “genetics-washing”: a general LIS or LIMS with a genetics label but shallow variant/PGx workflows.
The six capabilities a genetic testing lab needs
1. LIS/LIMS operations
The core: order intake, accessioning, specimen tracking, statuses, batches and runs, users, roles, and review queues. Genetic labs are sample-centric (like a LIMS) but produce patient-centric clinical results (like a LIS), so the operational layer needs to do both. See LIS vs LIMS for why that matters.
2. Reporting
Branded, customizable clinical reports — PGx, hereditary cancer, carrier screening, molecular results — with a real review-and-approval workflow. For genetics specifically, the platform should understand variant and diplotype reporting, not just generic result fields.
3. Integrations
HL7 and FHIR-ready connectivity to EMR/EHR systems, plus instrument and system interfaces. Interoperability is increasingly an expectation, not a nice-to-have.
4. Provider & patient portals
Secure, branded access for ordering providers and patients — ordering, status, report access, and communication — so delivery isn't scattered across email and PDFs.
5. Billing / RCM
Genetic and molecular tests are often high-cost and prior-authorization heavy. Billing that starts at the order — eligibility, coding, claim status, denials — protects revenue. When billing is bolted on after the fact, clean-claim rates suffer.
6. Security & compliance
Genetic data is among the most sensitive in healthcare. Look for HIPAA compliance, role-based access, audit logs, encryption, and ideally SOC 2 / ISO 27001-backed security with BAAs available.
One platform vs a stitched stack
Many labs end up running a LIMS for samples, a separate tool for reports, a portal product, and a billing system — connected by spreadsheets and manual re-keying. That works until it doesn't: every hand-off is a place for delay, duplicate entry, and errors. An integrated platform keeps one record from order to report to claim. The trade-off is flexibility vs cohesion — but for most genetic labs, cohesion wins because the workflow is so tightly coupled.
How to run the evaluation
- Map your real workflow first — order to accessioning to run to report to delivery to claim — and score each vendor against every step.
- Test genetics depth. Ask to see variant/PGx reporting, not a generic result template.
- Check the billing story. Does revenue cycle start at the order, or is it a separate system?
- Probe integrations. HL7/FHIR scope, EMR/EHR, instruments — and who does the interface work.
- Verify security. HIPAA, SOC 2, ISO 27001, BAAs, audit logs, RBAC.
- Understand AI. Does it assist review or try to replace it? It should assist.
- Plan implementation. Migration from a legacy system is often the hardest part — ask how it's handled.
Where Labrynix fits
Labrynix is an integrated LIS/LIMS hybrid built specifically for genetic, molecular, and PGx labs — covering all six capabilities on one record: operations, reporting, integrations, portals, billing, and security, with AI that assists qualified review. Explore the fit by lab type on the solutions pages.
Frequently asked questions
Is a LIMS enough for a genetic testing lab?
Usually not on its own. A LIMS handles samples well but typically lacks the patient-centric reporting, portals, and billing a clinical genetic lab needs. A LIS/LIMS hybrid covers both.
What's the most overlooked capability?
Billing/RCM. Genetic tests are high-cost and prior-auth heavy, so revenue cycle that starts at the order — not after the report — has outsized impact on a lab's margins.